Prognostic implications of additional chromosome abnormalities among patients with de novo acute promyelocytic leukemia with t(15;17)

Peter H. Wiernik, Zhuoxin Sun, Holly Gundacker, Gordon Dewald, Marilyn L. Slovak, Elisabeth Paietta, Haesook T. Kim, Frederick R. Appelbaum, Peter A. Cassileth, Martin S. Tallman

Research output: Contribution to journalArticle

12 Scopus citations

Abstract

This retrospective study performed by the Eastern Cooperative Oncology Group and the Southwest Oncology Group enrolled 140 acute promyelocytic leukemia (APL) patients with t(15;17) to determine the influence of additional karyotypic abnormalities on treatment outcome. Karyotypes were centrally reviewed by both study groups. The complete response rate after induction for patients with t(15;17) treated with chemotherapy, or alltrans retinoic acid (ATRA) as induction therapy was not affected by additional cytogenetic aberrations. Disease-free (DFS) and overall survival (OS) were unaffected by additional cytogenetic abnormalities if treatment was chemotherapy without ATRA. Patients with t(15;17) only, treated with ATRA with or without chemotherapy, had an improved DFS (P = 0.06) and a better OS (P = 0.01) compared with ATRA-treated patients with additional cytogenetic abnormalities. Patients with APL and t(15;17) alone are significantly more sensitive to treatment with ATRA than are patients with t(15;17) and additional cytogenetic abnormalities.

Original languageEnglish (US)
Pages (from-to)2095-2101
Number of pages7
JournalMedical Oncology
Volume29
Issue number3
DOIs
StatePublished - Sep 1 2012
Externally publishedYes

    Fingerprint

Keywords

  • Acute promyelocytic leukemia
  • All-trans retinoic acid
  • Karyotype
  • T(15;17)

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Wiernik, P. H., Sun, Z., Gundacker, H., Dewald, G., Slovak, M. L., Paietta, E., Kim, H. T., Appelbaum, F. R., Cassileth, P. A., & Tallman, M. S. (2012). Prognostic implications of additional chromosome abnormalities among patients with de novo acute promyelocytic leukemia with t(15;17). Medical Oncology, 29(3), 2095-2101. https://doi.org/10.1007/s12032-012-0251-7